Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 55,555,556 shares of common stock (or pre-funded warrants in lieu thereof). Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $2.25. The aggregate gross proceeds from the offering are expected to be approximately $125.0 million (assuming no exercise of the common stock warrants), before deducting underwriting discounts and commissions and offering expenses. If all of the common stock warrants are exercised at their exercise price, the Company would receive additional gross proceeds from the offering of approximately $194.4 million before deducting underwriting discounts and commissions and offering expenses.

Each common stock warrant will be exercisable for shares of common stock (or pre-funded warrants in lieu thereof), will have an exercise price of $3.50 per share (or $3.4999 per share if exercised for pre-funded warrants), will be exercisable immediately and will expire on the earlier of (i) the date that is thirty (30) days following the first public announcement by the Company of Phase 1 clinical data for the Company's product candidate, EDIT-401, that discloses at least three patients in the trial that each demonstrated greater than 80% reduction in LDL-cholesterol as compared to baseline with at least one (1) month of follow-up and (ii) three years from the date of issuance. Any pre-funded warrants issued upon the exercise of common stock warrants will have an exercise price of $0.0001 per share of common stock, will be immediately exercisable and will expire on the date the pre-funded warrant is exercised in full.

All of the securities in the offering are being sold by Editas Medicine. The offering is expected to close on or about May 27, 2026, subject to satisfaction of customary closing conditions.